Second Quarter 2026
Filed Aug 12, 2026Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Lexeo initiated the SUNRISE-FA 2 pivotal study, received RMAT designation for LX2020, and reported cash, cash equivalents, and investments of $234.2 million expected to fund operations into 2028. The company remained loss-making, with research and development expense increasing year over year.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and Development Expenses, three months ended June 30, 2026GAAP | $19.0 million | – | – |
| General and Administrative Expenses, three months ended June 30, 2026GAAP | $9.0 million | – | – |
| Total operating expenses, three months ended June 30, 2026GAAP | $ 28,020 | – | – |
| Operating loss, three months ended June 30, 2026GAAP | $ (28,020 ) | – | – |
| Gain on long-term investment, three months ended June 30, 2026GAAP | - | – | – |
| Other expense, net, three months ended June 30, 2026GAAP | $ (6 ) | – | – |
| Interest expense, three months ended June 30, 2026GAAP | $ (14 ) | – | – |
| Interest income, three months ended June 30, 2026GAAP | $ 2,194 | – | – |
| Amortization of premium accretion of discount on investments in U.S. Treasury securities, net, three months ended June 30, 2026GAAP | $ (21 ) | – | – |
| Total other income and expense, three months ended June 30, 2026GAAP | $ 2,153 | – | – |
| Loss from operations before income taxes, three months ended June 30, 2026GAAP | $ (25,867 ) | – | – |
| Income taxes, three months ended June 30, 2026GAAP | - | – | – |
| Net loss, three months ended June 30, 2026GAAP | $25.9 million | – | – |
| Net loss per common share, basic and diluted, three months ended June 30, 2026GAAP | $0.30 per share (basic and diluted) | – | – |
| Weighted average number of shares outstanding used in computation of net loss per common share, basic and diluted, three months ended June 30, 2026GAAP | 85,626,751 | – | – |
| Research and development, six months ended June 30, 2026GAAP | $ 34,730 | – | – |
| General and administrative, six months ended June 30, 2026GAAP | 15,623 | – | – |
| Total operating expenses, six months ended June 30, 2026GAAP | 50,353 | – | – |
| Operating loss, six months ended June 30, 2026GAAP | (50,353 ) | – | – |
| Total other income and expense, six months ended June 30, 2026GAAP | 4,290 | – | – |
| Net loss, six months ended June 30, 2026GAAP | $ (46,063 ) | – | – |
| Net loss per common share, basic and diluted, six months ended June 30, 2026GAAP | $ (0.55 ) | – | – |
| Weighted average number of shares outstanding used in computation of net loss per common share, basic and diluted, six months ended June 30, 2026GAAP | 83,417,555 | – | – |
| Cash, cash equivalents, and investments in marketable securities, as of June 30, 2026other | $234.2 million | – | – |
Into 2028 outlook
- NoteCash, cash equivalents, and investments in marketable securities were $234.2 million, which Lexeo believes will be sufficient to fund operations into 2028.
- NoteTopline data readout expected in second half of 2027.
- NotePotential BLA submission under accelerated approval pathway in first half of 2028.
- Note12-month data update for all high dose participants in Q4 2026.
- NoteRegulatory engagement with the FDA expected in 2026.
- NoteContinued FDA engagement on confirmatory evidence strategy; update expected once finalized.
What drove it
- SUNRISE-FA 2 was initiated in June with activation of the first trial site and enrollment of the first patient.
- CLARITY-FA enrollment continues to advance across multiple sites in the US and globally, with enrolled patients eligible to participate in SUNRISE-FA 2.
- The FDA granted RMAT designation for LX2020 based on recent interim data from the ongoing Phase I/II clinical trial in PKP2-ACM.
- LX2020 remains generally well tolerated across ten participants dosed with no clinically significant complement activation to date.
Concerns
- Lexeo reported a net loss of $25.9 million for the three months ended June 30, 2026.
- Research and Development expenses were $19.0 million for the three months ended June 30, 2026, compared to $14.7 million for the three months ended June 30, 2025.
- The company stated that continued FDA engagement is needed on the confirmatory evidence strategy.
- Topline data from SUNRISE-FA 2 are expected in the second half of 2027.
What to watch
- Ongoing SUNRISE-FA 2 site activation and continued enrollment in the pivotal study.
- The update on the LX2006 confirmatory evidence strategy once finalized.
- The 12-month data update for all high dose LX2020 participants in Q4 2026.
- Regulatory engagement with the FDA for LX2020 expected in 2026.
- LX2006 topline data expected in the second half of 2027 and a potential BLA submission in the first half of 2028.
Balance sheet and cash flow
- Cash, cash equivalents, and investments in U.S. Treasury securities were $ 234,171 as of June 30, 2026, compared to $ 246,568 as of December 31, 2025.
- Total assets were 254,898 as of June 30, 2026, compared to 268,688 as of December 31, 2025.
- Total liabilities were 19,837 as of June 30, 2026, compared to 22,019 as of December 31, 2025.
- Total stockholders' equity was 235,061 as of June 30, 2026, compared to 246,669 as of December 31, 2025.
Analysis
Lexeo's quarter was defined by clinical and regulatory execution rather than commercial performance. The company finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan for LX2006 under the accelerated approval pathway. It initiated the study in June, including first-site activation and enrollment of the first patient. CLARITY-FA enrollment continued across US and global sites, with enrolled patients eligible for SUNRISE-FA 2 as trial sites become active.
LX2020 added a second development catalyst. The FDA granted RMAT designation in August 2026 based on recent interim data in PKP2-ACM. Lexeo reported that LX2020 was generally well tolerated across ten participants dosed, with no clinically significant complement activation to date. The stated next milestones are a 12-month update for all high-dose participants in Q4 2026 and FDA regulatory engagement in 2026.
The income statement reflects a clinical-stage operating model with no reported revenue. Research and development expense was $19.0 million for the three months ended June 30, 2026, versus $14.7 million in the prior-year period, while general and administrative expense was $9.0 million versus $16.0 million. Total operating expenses were $ 28,020, compared with $ 30,688, and net loss was $25.9 million, compared with $26.1 million. Interest income was $ 2,194, compared with $ 1,268.
Liquidity remains central to the development plan. Cash, cash equivalents, and investments in marketable securities were $234.2 million as of June 30, 2026, which the company expects will fund operations into 2028. The cash, cash equivalents, and investments in U.S. Treasury securities balance was $ 234,171, compared with $ 246,568 as of December 31, 2025. There were no reported operating cash flow, free cash flow, debt, share repurchases, or dividends in the filing.
The principal value-inflection timetable is long-dated. Lexeo expects continued FDA engagement on the LX2006 confirmatory evidence strategy, a SUNRISE-FA 2 topline data readout in the second half of 2027, and a potential accelerated-approval BLA submission in the first half of 2028. Execution on site activation and enrollment, the Q4 2026 LX2020 update, and the durability of the stated cash runway are the reported items that warrant attention.
Management, verbatim
We closed the second quarter with significant momentum, highlighted by the initiation of SUNRISE-FA 2, the pivotal study for LX2006 in Friedreich ataxia cardiomyopathy.
R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics
Beyond LX2006, we continue to advance LX2020 in PKP2 arrhythmogenic cardiomyopathy and are pleased to have recently received RMAT designation from the FDA, an important milestone that reinforces the strength of the emerging clinical evidence and supports the potential expedited development of the program.
R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics
Not in the filing
stated, not guessed- Total revenue
- Revenue comparisons and revenue growth rates
- Segment revenue and segment growth rates
- Gross profit and gross margin
- GAAP net income
- Non-GAAP revenue, gross margin, operating income, net income, and EPS
- Prior-quarter comparisons for reported income-statement metrics
- Percentage changes for reported income-statement metrics
- Operating cash flow
- Free cash flow
- Debt
- Share repurchases
- Dividends
- Numeric revenue, gross-margin, operating-expense, and tax-rate guidance
- Previous-quarter outlook for comparison
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.